RANDOMIZED COMPARISON OF TWO APPROACHES TO WARFARIN DOSAGE IN CARDIOVASCULAR HOSPITAL SECTION

kod QR

RANDOMIZED COMPARISON OF TWO APPROACHES TO WARFARIN DOSAGE IN CARDIOVASCULAR HOSPITAL SECTION

Aim. To compare two approaches to warfarin dosage formulation: the standard and with the clinical algorithm.Material and methods. As an approach to warfarin dosage, we have used the method that included clinical properties of the patients. Into the group of the studied approach (intervention group),...

Szczegółowa specyfikacja

Zapisane w:

Opis bibliograficzny
Główni autorzy:	L. N. Mishchenko, O. V. Averkov, I. G. Gordeev, E. E. Tyulkina, E. P. Pavlikova, N. N. Levchuk, I. G. Pletnikova
Format:	Artykuł
Język:	rosyjski
Wydane:	«FIRMA «SILICEA» LLC 2015-08-01
Seria:	Российский кардиологический журнал
Hasła przedmiotowe:	warfarin warfain dose selection inr stable inr clinical algorithm standard approach
Dostęp online:	https://russjcardiol.elpub.ru/jour/article/view/183
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

The Value of Using Bedside Point of Care Testing for International Normalized Ratio in Patients on Warfarin Undergoing Dental Procedures and Bleeding Assessment; A Single Center Prospective Study
od: Albarkheel A, i wsp.
Wydane: (2025-07-01)

ОЦЕНКА ТЕРАПЕВТИЧЕСКОЙ ЭФФЕКТИВНОСТИ ВАРФАРИНА ПРОИЗВОДСТВА ЗАО «КАНОНФАРМА ПРАДАКШЕН» (РОССИЯ)
od: М. В. Хруслов, i wsp.
Wydane: (2014-02-01)

THE CONTROL OF INTERNATIONAL NORMALISED RATIO IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH WARFARIN IN OUTPATIENT AND HOSPITAL SETTINGS: DATA FROM RECVASA REGISTRIES
od: M. M. Loukianov, i wsp.
Wydane: (2018-03-01)

Alternative therapy interaction with warfarin: what doctors should know
od: T. B. Kozlova, i wsp.
Wydane: (2010-06-01)

Quality of Anticoagulation Management with Warfarin among Patients in Orotta National Referral Hospital, Asmara, Eritrea: A Retrospective Cross-Sectional Study
od: Natnael Russom, i wsp.
Wydane: (2022-10-01)

INCREASED ADHERENCE TO WARFARIN TREATMENT WITH TRAINING PROGRAMS IN PATIENTS WITH ATRIAL FIBRILLATION
od: E. D. Djishambaev, i wsp.
Wydane: (2020-12-01)

MONITORING OF ANTICOAGULANT THERAPY IN PATIENTS WITH DEEP VEIN THROMBOSIS
od: V. I. Petrov, i wsp.
Wydane: (2014-08-01)

Cholestyramine: an inexpensive but overlooked treatment for long-acting anticoagulant rodenticide (LAAR) poisoning
od: Israel Rubinstein, i wsp.
Wydane: (2024-12-01)

Impact of thromboplastin reagents on monitoring INR in a patient with triple-positive antiphospholipid syndrome: a case report
od: Lóránt Varju, i wsp.
Wydane: (2025-07-01)

Rapid Initiation of Antiretroviral Therapy Suppresses T Cell Pathological Proliferation and Improves Immune Recovery in People Living with HIV
od: Ji J, i wsp.
Wydane: (2025-07-01)

SPECIAL CONSIDERATIONS REGARDING WARFARIN DOSE TITRATION IN PATIENTS WITH ATRIAL FIBRILLATION DEPENDING ON CLINICAL FACTORS
od: E. L. Artanova, i wsp.
Wydane: (2016-01-01)

Hyperspectral Image Joint Super-Resolution via Local Implicit Spatial-Spectral Function Learning
od: Yanan Zhang, i wsp.
Wydane: (2024-01-01)

WARFARIN IN PATIENTS WITH CARDIOEMBOLIC STROKE
od: E. N. Dankovtseva, i wsp.
Wydane: (2015-12-01)

Gastrointestinal Bleeding: a Cardiologist's Point of View
od: O. V. Averkov, i wsp.
Wydane: (2021-11-01)

The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
od: I. Yu. Koroleva, i wsp.
Wydane: (2016-11-01)

Diagnosis of Impairments in the Hemostatic System in the Use of Warfarin in Cardiac Surgical Patients
od: E. I. Goncharova, i wsp.
Wydane: (2015-09-01)

Control-Relevant Adaptive Personalized Modeling From Limited Clinical Data for Precise Warfarin Management
od: Affan Affan, i wsp.
Wydane: (2022-01-01)

Clinical Case: Atypical Warfarin-induced Skin Necrosis
od: T. V. Kondratieva, i wsp.
Wydane: (2019-11-01)

ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION
od: Yu. B. Belousov, i wsp.
Wydane: (2016-01-01)

SYNTHESIS, PHYSICO-CHEMICAL ANALYSIS AND PHARMACOLOGICAL ACTIVITY OF SOME DERIVATIVES OF WARFARIN
od: A. Z. Abyshev, i wsp.
Wydane: (2019-01-01)

SAFETY OF LONGTERM THERAPY WITH WARFARIN: POSSIBILITY OF TREATMENT RENEWING AFTER HEMORRHAGIC COMPLICATIONS
od: E. S. Kropacheva
Wydane: (2016-01-01)

Decrease in Efficacy of Warfarin as a Result of Drug-Drug Interaction (Case Report)
od: N. T. Vatutin, i wsp.
Wydane: (2020-03-01)

THE INVASIVE DENTAL PROCEDURES IN PATIENTS TREATING WITH WARFARIN: POSSIBILITIES AND PROSPECTS FOR SAFETY
od: T. V. Kozlova, i wsp.
Wydane: (2016-01-01)

Nontraumatic warfarin-related intrapulmonary hemorrhage presenting as a lung mass
od: Hiroyuki Tsuchida, i wsp.
Wydane: (2020-04-01)

A Case of Gastrointestinal Hemorrage Due to Warfarin Interaction with Nalidixic Acid Resulting in Massive Blood Loss
od: D. A. Sychev, i wsp.
Wydane: (2020-05-01)

CYP2C9*2 and CYP2C9*3 allele variants of CYP2C9 cytochrome gene in St. Petersburg population, and their clinical role in warfarin anticoagulant therapy
od: O. V. Sirotkina, i wsp.
Wydane: (2004-12-01)

ANALYSIS OF STRUCTURAL FEATURES OF THE KETO-KETAL ISOMERS OF WARFARIN BY SPECTRAL METHODS
od: A. Z. Abyshev, i wsp.
Wydane: (2019-01-01)

Pharmacogenetic Warfarin Dosing Algorithm in the Russian Population
od: T. A. Bairova, i wsp.
Wydane: (2019-07-01)

COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE
od: L. E. Kuvshinova, i wsp.
Wydane: (2015-09-01)

Efficacy and safety of combined aspirin and warfarin therapy after heart valve replacement: a systematic review and meta-analysis of randomized clinical trials
od: E. Z. Golukhova, i wsp.
Wydane: (2022-09-01)

TIME IN THERAPEUTIC RANGE (TTR) IN ATRIAL FIBRILLATION WITH WARFARIN THERAPY IN SEMARANG, INDONESIA
od: Della Dafina Sekarsari, i wsp.
Wydane: (2021-10-01)

CYTOCHROME P450 (CYP2C9) ACTIVENESS, EVALUATED VIA LOSARTAN TEST, AS PREDICTION MARKER FOR THE WARFARIN TREATMENT DOSAGE CHOICE IN PATIENTS WITH DELAYED OUTCOMES AFTER HEART VALVES REPLACEMENT
od: S. M. Arslanbekova, i wsp.
Wydane: (2015-10-01)

Excessive Hypocoagulation in Therapy with Warfarin within Polypharmacy: Using online database Multi-Drug Interaction Checker and Graphic “Time-Effect-Drug Administration” to Eliminate Adverse Drug Event (Case Report)
od: G. S. Krasnov, i wsp.
Wydane: (2018-11-01)

ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT
od: E. L. Dolgova, i wsp.
Wydane: (2015-09-01)

ANALISA GAMBARAN POST MORTEM MAKROSKOPIS DAN MIKROSKOPIS ORGAN PARU DAN USUS HALUS PADA TIKUS WISTAR SETELAH PEMBERIAN WARFARIN LD-50 DAN LD-100
od: Mada Aji Prakoso, i wsp.
Wydane: (2016-04-01)

PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
od: Yu. B. Belousov, i wsp.
Wydane: (2015-12-01)

Warfarin hypersensitivity in the internist's practice: a case report
od: E. S. Levitskaya, i wsp.
Wydane: (2023-02-01)

WARFARIN AND ITS IMPORTANCE IN THE ERA OF NEW ORAL ANTICOAGULANTS. ISSUES OF MONITORING THE EFFECTIVENESS AND SAFETY OF TREATMENT
od: S. Yu. Martsevich, i wsp.
Wydane: (2017-11-01)

Efficiency of the Left Atrial Appendage Thrombus Dissolution in Patients with Persistent Nonvalvular Atrial Fibrillation with Warfarin or Direct Oral Anticoagulants Therapy
od: E. S. Mazur, i wsp.
Wydane: (2021-11-01)

Analisa Gambaran Post Mortem Makroskopis dan Mikroskopis Organ Jantung dan Ginjal pada Tikus Wistar Setelah Pemberian Warfarin LD50 dan LD 100
od: Anggoro Adjar Mangestu, i wsp.
Wydane: (2016-04-01)